Home > Boards > US Listed > Biotechs > Sorrento Therapeutics, Inc. (SRNE)

Sorrento has no cure, but perhaps can provide

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
r clarke Member Profile
 
Followed By 12
Posts 3,353
Boards Moderated 0
Alias Born 11/16/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/29/2020 9:01:33 AM
Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression... GlobeNewswire Inc. - 10/29/2020 9:00:10 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/22/2020 5:26:19 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/22/2020 5:26:12 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/21/2020 4:17:18 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/21/2020 6:05:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/20/2020 5:22:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/20/2020 9:01:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/16/2020 4:31:25 PM
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib i... GlobeNewswire Inc. - 10/14/2020 11:56:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2020 6:04:05 AM
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COV... GlobeNewswire Inc. - 10/12/2020 5:20:59 PM
Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released GlobeNewswire Inc. - 10/9/2020 7:46:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2020 1:09:05 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/8/2020 5:23:03 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 10/8/2020 4:16:35 PM
Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Stud... GlobeNewswire Inc. - 10/7/2020 3:09:42 PM
Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to C... GlobeNewswire Inc. - 10/7/2020 6:00:10 AM
Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline GlobeNewswire Inc. - 10/4/2020 6:39:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2020 4:16:45 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 9/30/2020 5:22:59 PM
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST... GlobeNewswire Inc. - 9/30/2020 9:26:45 AM
Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVI... GlobeNewswire Inc. - 9/30/2020 9:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/29/2020 6:08:09 AM
Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Ag... GlobeNewswire Inc. - 9/28/2020 11:59:34 PM
r clarke   Monday, 05/18/20 07:36:04 AM
Re: AlwaysOptimistic post# 2629
Post # of 6938 
Sorrento has no cure, but perhaps can provide preventative measures so
we can get back to "normal".

The release says that Sorrento “aims to generate an antibody cocktail product that would act as a ‘protective shield’ against SARS-CoV-2 coronavirus infection and remain effective even if virus mutations render a single antibody therapy less effective over time.”





"Sorrento may have found the Cure! Time will tell. Wishing them and all pharmas best of Luck!"

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences